Pred-462 |top| ✮

PRED‑462 – A Brief Overview

Research on PRED-462 has focused on its potential therapeutic applications, particularly in the treatment of:

Pharmacodynamics:

In xenograft mouse models, oral dosing (10 mg/kg, once daily) produced > 70 % tumor growth inhibition (TGI) over 28 days, with plasma exposure (C max ≈ 2 µM) well above the in‑vitro IC 50 . PRED-462

Exact Molecular Target

| Question | Current Knowledge | What Remains to Be Determined | |----------|-------------------|------------------------------| | | Patent and abstract hint at PI3Kδ/ER binding. | Confirmation via crystallography or proteomics. | | Biomarker Strategy | Preliminary work on phospho‑AKT levels. | Validation of predictive biomarkers (e.g., PIK3CA mutations). | | Resistance Mechanisms | In‑vitro selection of resistant clones shows upregulation of ABC transporters. | Clinical relevance of resistance pathways. | | Formulation | Cyclodextrin‑based oral suspension used in animal studies. | Final dosage form (tablet vs. solution) and bioavailability in humans. | | Regulatory Path | IND cleared in the U.S.; IND‑like submissions planned for EU/JP. | Timeline for NDA/MAA submission contingent on Phase II data. | PRED‑462 – A Brief Overview Research on PRED-462

Review for PRED-462: Policy, Research, and Evaluation Design or Methods

(Note: This is a structured template, as specific details about PRED-462 are not provided. It can be adapted based on the course’s actual content.) Conceptualization: Interpret "PRED-462" as a theme

• Conceptualization: Interpret "PRED-462" as a theme, title, or inspiration for your art piece.
• Execution: Create the piece based on your interpretation. This could involve painting, digital art, writing a story or poem, or composing music.